Cite
Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study.
MLA
Pakkala, Suchita, et al. “Durvalumab and Tremelimumab with or without Stereotactic Body Radiation Therapy in Relapsed Small Cell Lung Cancer: A Randomized Phase II Study.” Journal for Immunotherapy of Cancer, vol. 8, no. 2, Dec. 2020. EBSCOhost, https://doi.org/10.1136/jitc-2020-001302.
APA
Pakkala, S., Higgins, K., Chen, Z., Sica, G., Steuer, C., Zhang, C., Zhang, G., Wang, S., Hossain, M. S., Nazha, B., Beardslee, T., Khuri, F. R., Curran, W., Lonial, S., Waller, E. K., Ramalingam, S., & Owonikoko, T. K. (2020). Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study. Journal for Immunotherapy of Cancer, 8(2). https://doi.org/10.1136/jitc-2020-001302
Chicago
Pakkala, Suchita, Kristin Higgins, Zhengjia Chen, Gabriel Sica, Conor Steuer, Chao Zhang, Guojing Zhang, et al. 2020. “Durvalumab and Tremelimumab with or without Stereotactic Body Radiation Therapy in Relapsed Small Cell Lung Cancer: A Randomized Phase II Study.” Journal for Immunotherapy of Cancer 8 (2). doi:10.1136/jitc-2020-001302.